Summit Therapeutics (SMMT) Net Income (2017 - 2024)

Summit Therapeutics (SMMT) has reported Net Income for 8 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2024.

• Quarterly Net Income fell 86.26% year-over-year to -$72.9 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$72.9 million (up 64.98% YoY) and the FY2024 annual result came in at -$1.9 billion, down 209.59% from the prior year.
• Net Income declined to -$72.9 million in Q4 2024 per SMMT's latest filing, from -$60.8 million in the prior quarter.
• Over the last five years, Net Income for SMMT reached as high as -$6.3 million in Q1 2020 and fell as low as -$544.5 million in Q1 2023.
• A 5-year average of -$54.2 million and a median of -$21.4 million in 2022 frame the typical range for Net Income.
• Annual changes were most pronounced in 2023 — Net Income sank 2324.91% — and 2024, when it soared 91.64%.
• Year by year, Net Income stood at -$13.5 million in 2020, then tumbled by 100.13% to -$27.1 million in 2021, then rose by 25.09% to -$20.3 million in 2022, then tumbled by 92.86% to -$39.1 million in 2023, then sank by 86.26% to -$72.9 million in 2024.
• According to Business Quant data, Net Income over the past three periods registered -$72.9 million, -$60.8 million, and -$62.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.